Aesculap, a division of B Braun Melsungen, has entered into an agreement with Osseon Therapeutics.
Under the agreement, Aesculap will distribute Osseon’s vertebral compression fracture (VCF) treatment devices including new CE marked Osseoflex SB (steerable balloon) device used to treat spinal fractures in selected regions of Europe and Asia.
Osseon CEO said John Stalcup said their new Osseoflex SB represents the most precise and controllable treatment device for vertebral compression fracture augmentation currently available to surgeons.
"Osseon is very excited to partner with Aesculap to distribute our game-changing Osseoplasty devices and procedures for VCF treatment to patients throughout Europe and the international community and provide state-of-the-art alternatives to the cumbersome devices and procedures currently used to treat fractures of the thoracic and lumbar spine," Stalcup said.